

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human LILRA4/CD85g/ILT7 in ELISA. No cross-reactivity with human LILRA1, LILRA2, LILRA3, LILRA5, LILRA6, LILRB2 and LILRB3 with ELISA was observed.
Source	Monoclonal Mouse IgG _{2A} Clone # 656656
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Mouse myeloma cell line, NS0derived human LILRA4/CD85g/ILT7 Glu24-Asn446 Accession # P59901
Conjugate	Alexa Fluor 594 Excitation Wavelength: 590 nm Emission Wavelength: 617 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

Neutralization Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

LILRA4, also known as ILT7 and CD85g, is an approximately 60-70 kDa variably glycosylated transmembrane protein that regulates immune cell activation (1). Mature human LILRA4 consists of a 423 amino acid (aa) extracellular domain (ECD) with four immunoglobulin-like domains, a 21 aa transmembrane segment, and a 32 aa cytoplasmic domain (2). Alternative splicing generates an additional isoform that lacks the signal peptide and a portion of the first Ig-like domain. LILRA4 is expressed on plasmacytoid dendritic cells (pDC) but is down-regulated in response to TLR9 signaling (3-5). Antibody mediated crosslinking of LILRA4 on pDC inhibits the production of type I interferons following TLR7 or TLR9 stimulation (3, 4, 6). It also blocks the up-regulation of CCR7 but enhances the up-regulation of Integrin β7 on TLR7/9-stimulated pDC (6). LILRA4 associates with the ITAM-containing adaptor protein Fcε R1γ (3, 4, 6), and this complex binds to cell surface BST2/Tetherin which is expressed on monocytes, plasmacytoid and myeloid dendritic cells, B cells, and activated CD4⁺ and CD8⁺ T cells (5, 8). This interaction inhibits the TLR-induced pDC production of type I interferons, IL-6, and TNF-α (8).

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.